Prognostic factors and corresponding nursing measures for patients with endometrial cancer: a systematic review and meta-analysis

Backgrounds: Endometrial cancer (EC) is a common gynecological malignant tumor, and its prognosis is affected by many factors. This study aimed to identify the key clinical factors associated with poor prognosis in patients with EC and propose targeted nursing interventions. Methods: The relevant literature on prognostic factors for EC patients was retrieved from PubMed, Elsevier and Web of Science, and the quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Meta-analysis of 10 studies (n = 5288 patients) was conducted via STATA 12.0 to evaluate associations between factors and overall survival. Results: Significant predictors included age (hazard ratio (HR) = 1.45, 95% confidence interval (CI): 1.10–1.91), history of diabetes (HR = 1.26, 95% CI: 1.02–1.56), abnormal nutritional score (HR = 1.84, 95% CI: 1.16–2.92) and elevated carbohydrate antigen 125 (CA125) levels (HR = 1.80, 95% CI: 1.21–2.69). Body mass index (BMI), metformin use, and neutrophil-to-lymphocyte ratio (NLR) showed no significant prognostic impact. Elderly patients should pay attention to comprehensive assessment and provide psychological support; Nutrition score abnormal patients need to make a weight management plan and reasonably arrange diet counseling; History of diabetes patients should be blood sugar monitoring, optimizing sugar control scheme. Conclusions: These findings suggest that age, nutrition score and history of diabetes may lead to poor prognosis in EC patients, and nursing interventions should focus on these factors to improve survival rates and enhance the quality of life of these patients. The INPLASY Registration: INPLASY2024110012.

Endometrial cancer; Prognosis prediction; Risk factors; Meta-analysis; Targeted nursing

[1] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[2] Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, et al. TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives. International Journal of Molecular Sciences. 2022; 23: 11684.

[3] Anca-Stanciu MB, Manu A, Olinca MV, Coroleucă BC, Comandaşu DE, Coroleucă CA, et al. Prognostic implications of immunohistochemistry in patients with endometrial cancer. Romanian Journal of Morphology and Embryology. 2024; 65: 185–193.

[4] Huang H, Cai X, Lin J, Wu Q, Zhang K, Lin Y, et al. A novel five-gene metabolism-related risk signature for predicting prognosis and immune infiltration in endometrial cancer: a TCGA data mining. Computers in Biology and Medicine. 2023; 155: 106632.

[5] Hoorshad N, Nassiri S, Najibi S, Feizabad E, Zamani N. Synchronous endometrial and ovarian cancer and its recurrent risk factors: case series. Cancer Treatment and Research Communications. 2023; 36: 100731.

[6] Hoang LN, Lee SJ. Casein kinase 1 controls the shuttling of epidermal growth factor receptor and estrogen receptor in endometrial carcinoma induced by breast cancer hormonal therapy: relevance of GPER1/Src. Cellular Signalling. 2023; 108: 110733.

[7] Jiang P, Yuan R. Analysis of factors related to lymph node metastasis in early-stage type 1 endometrial cancer: verifying the clinical value of positive threshold of the immunohistochemical parameter Ki67. Cancer Management and Research. 2021; 13: 6319–6328.

[8] Yoneoka Y, Amano T, Tsuji S, Uno M, Ishikawa M, Kato T, et al. The efficacy of adjuvant chemotherapy on the survival of early stage endometrial cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2023; 287: 155–160.

[9] Wang W, Li X, Gao Y, Zheng H, Gao M. A nomogram prediction model for the TP53mut subtype in endometrial cancer based on preoperative noninvasive parameters. BMC Cancer. 2023; 23: 720.

[10] Al Hilli MM, Bakkum-Gamez JN, Mariani A, Cliby WA, Mc Gree ME, Weaver AL, et al. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecologic Oncology. 2016; 140: 270–276.

[11] Anic K, Schmidt MW, Schmidt M, Krajnak S, Löwe A, Linz VC, et al. Impact of perioperative red blood cell transfusion, anemia of cancer and global health status on the prognosis of elderly patients with endometrial and ovarian cancer. Frontiers in Oncology. 2022; 12: 967421.

[12] Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K, et al. Preoperative neutrophil: lymphocyte and platelet: lymphocyte ratios predict endometrial cancer survival. British Journal of Cancer. 2015; 113: 311–320.

[13] Donkers H, Fasmer KE, McGrane J, Pijnenborg JMA, Bekkers R, Haldorsen IS, et al. Obesity and visceral fat: survival impact in high-grade endometrial cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021; 256: 425–432.

[14] Kiuchi K, Hasegawa K, Ochiai S, Motegi E, Kuno T, Kosaka N, et al. Prognostic significance of inflammatory parameters and nutritional index in clinical stage IVB endometrial carcinomas. Journal of Obstetrics and Gynaecology. 2019; 39: 237–241.

[15] Kolehmainen A, Pasanen A, Tuomi T, Koivisto-Korander R, Butzow R, Loukovaara M. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. PLOS ONE. 2020; 15: e0242733.

[16] Lemanska A, Zaborowski M, Spaczynski M, Nowak-Markwitz E. Do endometrial cancer patients benefit from metformin intake? Polish Gynaecology. 2015; 86: 419–423.

[17] Li Q, Cong R, Wang Y, Kong F, Ma J, Wu Q, et al. Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study. Gynecologic Oncology. 2021; 160: 91–98.

[18] Seebacher V, Bergmeister B, Grimm C, Koelbl H, Reinthaller A, Polterauer S. The prognostic role of metformin in patients with endometrial cancer: a retrospective study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016; 203: 291–296.

[19] Yuan J, Wang Q, Cheng J, Wang J, Zhang Y. Using preoperative control nutritional status scores as prognostic factors for endometrial cancer. Frontiers in Oncology. 2023; 13: 1126576.

[20] Lim H, Kim SI, Kim MK, Yoon SH, Lee M, Suh DH, et al. Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: an artificial intelligence-based volumetric study. Gynecologic Oncology. 2024; 190: 200–208.

[21] Giannini A, D’Oria O, Corrado G, Bruno V, Sperduti I, Bogani G, et al. The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics. 2024; 309: 789–799.

[22] Xiao JP, Wang JS, Zhao YY, Du J, Wang YZ. Microsatellite instability as a marker of prognosis: a systematic review and meta-analysis of endometrioid endometrial cancer survival data. Archives of Gynecology and Obstetrics. 2023; 307: 573–582.

[23] Travaglino A, Raffone A, Raimondo D, Reppuccia S, Ruggiero A, Arena A, et al. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics. 2022; 306: 423–431.

[24] Mamat Yusof MN, Chew KT, Kampan N, Abd Aziz NH, Md Zin RR, Tan GC, et al. PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis. Cancers. 2022; 14: 3911.

[25] Jin X, Shen C, Yang X, Yu Y, Wang J, Che X. Association of tumor size with myometrial invasion, lymphovascular space invasion, lymph node metastasis, and recurrence in endometrial cancer: a meta-analysis of 40 studies with 53,276 patients. Frontiers in Oncology. 2022; 12: 881850.

[26] Zhang M, Li R, Zhang S, Xu X, Liao L, Yang Y, et al. Analysis of prognostic factors of metastatic endometrial cancer based on surveillance, epidemiology, and end results database. Frontiers in Surgery. 2023; 9: 1001791.

[27] Åkesson Å, Adok C, Dahm-Kähler P. Recurrence and survival in endometrioid endometrial cancer—a population-based cohort study. Gynecologic Oncology. 2023; 168: 127–134.

[28] Njoku K, Ramchander NC, Wan YL, Barr CE, Crosbie EJ. Pre-treatment inflammatory parameters predict survival from endometrial cancer: a prospective database analysis. Gynecologic Oncology. 2022; 164: 146–153.

[29] Barczyński B, Frąszczak K, Wnorowski A, Kotarski J. Menopausal status contributes to overall survival in endometrial cancer patients. Cancers. 2023; 15: 451.

[30] Seke Etet PF, Vecchio L, Nwabo Kamdje AH, Mimche PN, Njamnshi AK, Adem A. Physiological and environmental factors affecting cancer risk and prognosis in obesity. Seminars in Cancer Biology. 2023; 94: 50–61.

[31] Huang P, Fan X, Yu H, Zhang K, Li H, Wang Y, et al. Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer. Journal of Translational Medicine. 2023; 21: 94.

[32] Ouasti S, Ilic J, Mimoun C, Bendifallah S, Huchon C, Ouldamer L, et al. Adherence to ESGO guidelines and impact on survival in obese patients with endometrial cancer: a multicentric retrospective study. International Journal of Gynecologic Cancer. 2023; 33: 1950–1956.

[33] Simon O, Dion L, Timoh KN, Dupré PF, Azaïs H, Bendifallah S, et al. Impact of severe obesity in the management of patients with high-risk endometrial cancer: a FRANCOGYN study. Journal of Gynecology Obstetrics and Human Reproduction. 2022; 51: 102429.

[34] Li X, Yang X, Cheng Y, Dong Y, Wang J, Wang J. Development and validation of a prognostic model based on metabolic risk score to predict overall survival of endometrial cancer in Chinese patients. Journal of Gynecologic Oncology. 2023; 34: e69.

[35] Wada M, Yamaguchi K, Yamakage H, Inoue T, Kusakabe T, Abiko K, et al. Visceral-to-subcutaneous fat ratio is a possible prognostic factor for type 1 endometrial cancer. International Journal of Clinical Oncology. 2022; 27: 434–440.

[36] Yoshida K, Kondo E, Ishida M, Ichikawa Y, Watashige N, Okumura A, et al. Visceral adipose tissue percentage compared to body mass index as better indicator of surgical outcomes in women with obesity and endometrial cancer. Journal of Minimally Invasive Gynecology. 2024; 31: 445–452.

[37] Cheng Y, Wang Z, Jia X, Zhou R, Wang J. Association between abdominal adipose tissue distribution and risk of endometrial cancer: a case-control study. Clinical Medicine Insights: Oncology. 2022; 16: 11795549221140776.

[38] Njoku K, Barr CE, Ramchander NC, Crosbie EJ. Impact of pre-treatment prognostic nutritional index and the haemoglobin, albumin, lymphocyte and platelet (HALP) score on endometrial cancer survival: a prospective database analysis. PLOS ONE. 2022; 17: e0272232.

[39] Thrastardottir TO, Copeland VJ, Constantinou C. The association between nutrition, obesity, inflammation, and endometrial cancer: a scoping review. Current Nutrition Reports. 2023; 12: 98–121.

[40] Vrede S, Donkers H, Reijnen C, Smits A, Visser N. Hematological parameters in endometrial cancer; worse prognosis reflecting tumor aggressiveness or reduced response to radiotherapy. Journal of Oncology. 2023; 3: 1092.

[41] Ionică M, Biris M, Gorun F, Nicolae N, Popa ZL, Muresan MC, et al. Predictive role of pre-operative anemia in early recurrence of endometrial cancer: a single-center study in Romania. Journal of Clinical Medicine. 2024; 13: 794.

[42] Dou Y, Song K, Fu Y, Shen Y, Zhang C, Yao S, et al. Risk factors and prognosis of early recurrence in stage I–II endometrial cancer: a large-scale, multi-center, and retrospective study. Frontiers in Medicine. 2022; 9: 808037.

[43] González P, Lozano P, Ros G, Solano F. Hyperglycemia and oxidative stress: an integral, updated and critical overview of their metabolic interconnections. International Journal of Molecular Sciences. 2023; 24: 9352.

[44] Angeles MA, Migliorelli F, Leon Ramirez LF, Ros C, Perissinotti A, Tapias A, et al. Predictive factors of preoperative sentinel lymph node detection in intermediate and high-risk endometrial cancer. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2023; 67: 37–45.

[45] Bogani G, Di Donato V, Papadia A, Buda A, Casarin J, Multinu F, et al. Hysterectomy alone vs. hysterectomy plus sentinel node mapping in endometrial cancer: perioperative and long-term results from a propensity-score based study. European Journal of Surgical Oncology. 2023; 49: 1037–1043.

[46] Cheng Y, Chen X, Hu D, Du J, Xing Y, Liang X, et al. Downregulation of ATP5F1D inhibits mtROS/NLRP3/caspase-1/GSDMD axis to suppress pyroptosis-mediated malignant progression of endometrial cancer. International Immunopharmacology. 2024; 139: 112808.